Xencor ( (XNCR) ) just unveiled an announcement.
Dagmar Rosa-Bjorkeson will not seek reelection to the Xencor, Inc. Board of Directors in the 2025 Annual Meeting, after serving since 2019 and contributing to the company’s strategic guidance and portfolio management. Xencor, a biopharmaceutical firm focused on engineered antibodies for cancer and other serious diseases, acknowledged her contributions and is looking to bring on new board members with complementary skills. Rosa-Bjorkeson’s departure is amicable and not due to any company disagreements.
See more insights into XNCR stock on TipRanks’ Stock Analysis page.
